(0.66%) 5 081.86 points
(0.13%) 38 134 points
(1.33%) 15 820 points
(0.84%) $84.27
(-5.49%) $1.548
(0.58%) $2 356.00
(0.83%) $27.58
(0.24%) $922.70
(0.20%) $0.934
(0.46%) $11.00
(0.04%) $0.800
(-0.36%) $91.84
@ $1.280
Issued: 14 Feb 2024 @ 09:35
Return: -17.19%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 11.20 %
Live Chart Being Loaded With Signals
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom...
Stats | |
---|---|
Today's Volume | 5 622.00 |
Average Volume | 2.05M |
Market Cap | 240.80M |
EPS | $0 ( 2024-03-04 ) |
Next earnings date | ( $-0.160 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.960 |
ATR14 | $0.00500 (0.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Ecor1 Capital, Llc | Buy | 0 | Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 5 088 864 | Option to purchase Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 1 130 832 | Option to purchase Ordinary Shares |
2024-01-17 | Rawcliffe Adrian | Sell | 30 080 | American Depositary Shares representing Ordinary Shares |
2024-01-16 | Rawcliffe Adrian | Sell | 9 304 | American Depositary Shares representing Ordinary Shares |
INSIDER POWER |
---|
96.16 |
Last 96 transactions |
Buy: 71 750 188 | Sell: 1 254 319 |
Volume Correlation
Adaptimmune Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
ASLN | 0.967 |
FBRX | 0.966 |
CLPT | 0.966 |
AGRX | 0.964 |
VLCN | 0.963 |
SOFO | 0.961 |
SCPH | 0.961 |
TELA | 0.959 |
SVRE | 0.958 |
ESTA | 0.958 |
10 Most Negative Correlations | |
---|---|
ADV | -0.976 |
MLAI | -0.97 |
RCMT | -0.969 |
NVSA | -0.967 |
MPRA | -0.965 |
SVRA | -0.965 |
SCOB | -0.964 |
KAII | -0.964 |
STCN | -0.964 |
BTWN | -0.963 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Adaptimmune Therapeutics Correlation - Currency/Commodity
Adaptimmune Therapeutics Financials
Annual | 2023 |
Revenue: | $60.51M |
Gross Profit: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2023 |
Revenue: | $60.51M |
Gross Profit: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2022 |
Revenue: | $27.15M |
Gross Profit: | $-100.58M (-370.48 %) |
EPS: | $-1.030 |
FY | 2021 |
Revenue: | $6.15M |
Gross Profit: | $6.15M (100.00 %) |
EPS: | $-1.020 |
Financial Reports:
No articles found.
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators